Cristiana Barradas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cristiana Barradas has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Osama Saher
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University
2 shared publications - Samantha Roudi
Karolinska Institutet
2 shared publications - Samir EL Andaloussi
Department of Laboratory Medicine, Unit for Biomolecular and Cellular Medicine, Karolinska Institutet, Stockholm, Sweden
2 shared publications - Alyssa C. Hill
University of Oxford
1 shared publication Annabelle Biscans
Nucleic Acid Therapeutics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
1 shared publication- Antonin Marquant
ICGM, Montpellier University, CNRS, ENSCM
1 shared publication
Latest Publications
- Open Access
Lipid–ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration
Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO’s biodistribution and promote extrahepatic activity, yet lipid-dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side-by-side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3-10-3 LNA gapmer ASO targeting the Malat1 long non-coding RNA. Lipid–ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue-level and cellular-level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi-organ efficacy compared to unconjugated ASO, but with pronounced tissue-specific differences. Single-cell sequencing of liver and heart transcriptomes revealed lipid-dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol-ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context-specific lipid design in ASO therapeutic development. Highlights: SC, fatty acid conjugates primarily potentiate hepatic over extrahepatic silencing SC, cholesterol conjugate confines silencing activity to the liver Single-cell sequencing reveals lipid conjugate-induced differential gene expression First study reporting evaluation of lipid-ASO functional activity in the CNS via ICV delivery Chol-ASO retention at CSF-facing membranes correlates with poor parenchymal activity Graphical
Open AccessLipid–ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration
Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO’s biodistribution and promote extrahepatic activity, yet lipid-dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side-by-side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3-10-3 LNA gapmer ASO targeting the Malat1 long non-coding RNA. Lipid–ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue-level and cellular-level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi-organ efficacy compared to unconjugated ASO, but with pronounced tissue-specific differences. Single-cell sequencing of liver and heart transcriptomes revealed lipid-dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol-ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context-specific lipid design in ASO therapeutic development. Highlights: SC, fatty acid conjugates primarily potentiate hepatic over extrahepatic silencing SC, cholesterol conjugate confines silencing activity to the liver Single-cell sequencing reveals lipid conjugate-induced differential gene expression First study reporting evaluation of lipid-ASO functional activity in the CNS via ICV delivery Chol-ASO retention at CSF-facing membranes correlates with poor parenchymal activity Graphical
- Open Access
Click Chemistry-Based Strategy for Modular Ligand Attachment to siRNAs: Toward Extrahepatic RNAi
Efficient extrahepatic delivery of siRNAs remains a major limitation for broadening their therapeutic potential. Using a modular, orthogonal click chemistry platform, we generated 28 siRNA conjugates varying in ligand class, valency, and spatial arrangement. Following systemic administration, fatty acid conjugates — particularly palmitic acid (C16) — outperformed sterol- and phospholipid-based designs in promoting extrahepatic gene silencing, with preferential activity observed in heart and skeletal muscle. Increasing ligand valency through 3′,5′-bis-conjugation generally enhanced activity compared to 5′-mono conjugation. Nevertheless, bis-C22 conjugates showed increased hepatic activity, suggesting a shift in tissue distribution linked to hydrophobicity. Architectural parameters further modulated outcomes: Branched 5′ C16 conjugates, bearing two lipids on one terminus, were markedly less active than their bis counterparts and required short PEG spacers to restore activity. Notably, bis-lipid conjugation strategies that enhanced extrahepatic activity for an siRNA did not translate to an ASO gapmer, underscoring modality-specific constraints. Together, these findings delineate structure-activity relationships and establish bis-fatty-acid conjugation as a robust design principle for achieving extrahepatic RNAi.
Open AccessClick Chemistry-Based Strategy for Modular Ligand Attachment to siRNAs: Toward Extrahepatic RNAi
Efficient extrahepatic delivery of siRNAs remains a major limitation for broadening their therapeutic potential. Using a modular, orthogonal click chemistry platform, we generated 28 siRNA conjugates varying in ligand class, valency, and spatial arrangement. Following systemic administration, fatty acid conjugates — particularly palmitic acid (C16) — outperformed sterol- and phospholipid-based designs in promoting extrahepatic gene silencing, with preferential activity observed in heart and skeletal muscle. Increasing ligand valency through 3′,5′-bis-conjugation generally enhanced activity compared to 5′-mono conjugation. Nevertheless, bis-C22 conjugates showed increased hepatic activity, suggesting a shift in tissue distribution linked to hydrophobicity. Architectural parameters further modulated outcomes: Branched 5′ C16 conjugates, bearing two lipids on one terminus, were markedly less active than their bis counterparts and required short PEG spacers to restore activity. Notably, bis-lipid conjugation strategies that enhanced extrahepatic activity for an siRNA did not translate to an ASO gapmer, underscoring modality-specific constraints. Together, these findings delineate structure-activity relationships and establish bis-fatty-acid conjugation as a robust design principle for achieving extrahepatic RNAi.